ADMA Biologics Inc (ADMA)

How it makes money

Almost all revenue comes from selling vials of finished immune globulin. ASCENIV, BIVIGAM and Nabi-HB are sold mainly through independent distributors and drug wholesalers acting as sales agents, plus specialty pharmacies serving hospitals, ambulatory and home infusion sites; ADMA's own specialty sales force and medical science liaisons promote the products to prescribers, while third-party payers and Medicaid rebates determine the net price actually collected. A small second stream comes from plasma itself: liters collected at ADMA BioCenters that are not needed to make ADMA's own products are sold to third-party customers under supply agreements or on the open spot market. There is no royalty, licensing or subscription component of any size; revenue tracks vials shipped, and every vial is constrained by a 7-to-12-month collection-to-release manufacturing cycle.

Revenue by segment

ASCENIV, which is now about seven-tenths of revenue, rests on a patented composition: U.S. Patent No. 9,107,906 covers pooled plasma with a standardized, elevated titer of RSV-neutralizing antibodies and the immunoglobulin made from it, and further patents cover related compositions and methods. Around the patents sit trade secrets the company describes as proprietary donor selection criteria, formulation methodologies, reagents and the anti-RSV microneutralization assay used to identify high-titer donors. Layered on top is the regulatory barrier common to plasma: collection centers and each finished product need separate FDA licences, and the 10-K states there are only four producers of plasma-derived products in the U.S. The advantage is real but bounded — the patents expire, competitors CSL Behring, Grifols and Takeda are far larger with lower cost structures, and new anti-FcRn drugs may displace part of general IVIG use.

Demand comes from patients whose immune system cannot make working antibodies. The filing describes primary immunodeficiency as a group of hereditary disorders whose patients typically receive monthly outpatient IVIG infusions and, in marked antibody deficiency, are generally dependent on that therapy for survival. That makes volumes largely independent of the economic cycle: a recession does not stop a monthly infusion. What actually moves ADMA's revenue is supply and adoption rather than the cycle — how much source and high-titer RSV plasma it can collect or buy, how much finished product its plant can release on a 7-to-12-month cycle, how many prescribers and payers adopt ASCENIV, and how reimbursement policy evolves. The company cites a 2024 industry report putting U.S. sales of immune and hyperimmune globulins at roughly $13 billion in 2024, expected to exceed $30 billion by 2033. The identifiable structural threat is substitution, not recession: the filing points to anti-FcRn drugs already approved in myasthenia gravis and in development for CIDP, ITP and pemphigus vulgaris, which may displace a subset of general IVIG use.

Key risks

• A handful of customers carries most of the revenue — The company discloses that two customers, BioCare and CuraScript, together accounted for roughly 73% of consolidated revenues in FY2025 (72% in FY2024 and in FY2023), and that two customers represented about 87% of accounts receivable at 31 December 2025. It states that losing any of these customers, or a material change in the revenue they generate, could have a material adverse effect on the business.
• Supply of source and high-titer plasma can become the binding constraint — Among its principal risk factors the company lists becoming supply-constrained if it cannot obtain adequate quantities of FDA-approved source and high-titer plasma with the right specifications, or other necessary raw materials; it also flags that there can be no assurance it will succeed in collecting and procuring an adequate supply of high-titer anti-RSV plasma, the input ASCENIV depends on.
• Dependence on third parties for filling, testing and part of the plasma — The company contracts third parties for filling, packaging, testing and labeling of the drug substance it manufactures and obtains source plasma from certain third parties. It warns that these services and raw materials may not arrive on time, in sufficient quantity or to specification, which could delay availability of finished product and hurt commercialization and revenue. It adds that third-party researchers, developers and vendors perform pre- and post-approval services partly outside its control.
• FDA inspections and post-approval restrictions on both segments — Both business segments, the facilities, suppliers and contractors are subject to periodic FDA and other regulatory inspections that can end in observations, notices, citations, warning letters or other enforcement action. Approved products could also face post-marketing restrictions or withdrawal from the market, and the company could incur substantial penalties for non-compliance or unanticipated problems after approval. Quality and compliance problems are listed separately as capable of causing a loss of customer confidence.
• Manufacturing scale-up may not keep pace with demand — The company warns it may be unable to expand its manufacturing processes to fulfil demand for its products, or to increase production capability by adding new equipment, including if it does not obtain the required FDA approvals for that equipment or those processes.
• Medicaid rebate accruals are estimates that can move results — Accruals for U.S. Medicaid rebates and other liabilities tied to immunoglobulin sales are estimates based on historical experience and assumptions. The company states these estimates are subject to change with actual results and other factors, and that any such change could materially affect its business, financial position and operating results.
• Profitability is recent and may not last; debt can be accelerated — The company notes that although it earned net income of $197.7 million in 2024 and $146.9 million in 2025, it lost $28.2 million in 2023 and has an accumulated deficit of $161.7 million since inception in 2004; it may not maintain profitability or positive cash flow. Separately, its senior secured credit facility with JPMorgan can be accelerated in specified circumstances, which may let the lender take possession of and dispose of the collateral.
• Market-size forecasts and label expansion may not deliver — The company cautions that estimates of market opportunity and forecasts of market and revenue growth in its filings may prove inaccurate, and that even if those markets grow as forecast its own business may not grow at similar rates. It also states that its ability to market or seek approval of ASCENIV for indications beyond primary immunodeficiency is limited unless additional clinical trials succeed and the FDA approves the required submission.

Top customers account for 73% of revenue

For FY2025 two customers, BioCare and CuraScript (Priority Healthcare Distribution), together represented approximately 73% of consolidated revenues, against 72% in each of FY2024 and FY2023 — so the concentration is structural, not a one-year accident. Both are attributable to the ADMA BioManufacturing segment; no customer of the Plasma Collection Centers segment exceeded 10% of consolidated revenue. The exposure is even sharper on the balance sheet: two customers accounted for about 87% of consolidated accounts receivable at 31 December 2025 (three customers, about 91%, a year earlier). These are distributors rather than end payers, so the underlying demand is spread across many infusion sites and insurers, but the cash still passes through very few hands. The company says it plans to diversify its distribution and customer network in 2026.